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Abstract
Introduction: Pre-temozolomide studies demonstrated that loss of the tumor suppressor gene PTEN held independent
prognostic significance in GBM patients. We investigated whether loss of PTEN predicted shorter survival in the
temozolomide era. The role of PTEN in the PI3K/Akt pathway is also reviewed.
Methods: Patients with histologically proven newly diagnosed GBM were identified from a retrospective database between
2007 and 2010. Cox proportional hazards analysis was used to calculate the independent effects of PTEN expression, age,
extent of resection, Karnofsky performance scale (KPS), and treatment on overall survival.
Results: Sixty-five percent of patients were men with median age of 63 years, and 70% had KPS$80. Most patients (81%)
received standard treatment (temozolomide with concurrent radiation). A total of 72 (47%) patients had retained PTEN
expression. Median overall survival (OS) was 19.1 months (95% CI: 15.0–22.5). Median survival of 20.0 months (95% CI: 15.0–
25.5) and 18.2 months (95% CI: 13.0–25.7) was observed in PTEN retained and PTEN loss patients, respectively (p=.71). PTEN
loss patients were also found to have amplifications of EGFR gene more frequently than patients with retained PTEN (70.8%
vs. 47.8%, p=.01). Multivariate analysis showed that older age (HR 1.64, CI: 1.02–2.63, p=.04), low KPS (HR 3.57, CI: 2.20–
5.79, p,.0001), and lack of standard treatment (HR 3.98, CI: 2.38–6.65, p,.0001) yielded worse survival. PTEN loss was not
prognostic of overall survival (HR 1.31, CI: 0.85–2.03, p=.22).
Conclusions: Loss of expression of PTEN does not confer poor overall survival in the temozolomide era. These findings
imply a complex and non-linear molecular relationship between PTEN, its regulators and effectors in the tumorigenesis of
glioblastoma. Additionally, there is evidence that temozolomide may be more effective in eradicating GBM cancer cells with
PTEN loss and hence, level the outcomes between the PTEN retained and loss groups.
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Introduction
Glioblastoma multiforme is the most common primary
malignant brain tumor in adults with an average survival time of
just over one year [1–7]. Even after standard treatment, which
includes surgery followed by concurrent temozolomide and
radiation (i.e. Stupp protocol), survival is only extended by an
average of 2.5 months [1,4,8]. As standard medical practice yields
little survival benefit, greater attention is being paid to personal-
ized treatment and correspondingly to the expression of specific
molecular markers with a goal to assess their possible therapeutic
as well as prognostic significance [1,5,9–11]. Tyrosine kinase
signal transduction pathways, especially epidermal growth factor
receptor (EGFR) driven proliferation play an integral role in the
pathogenesis of gliomas [1,12]. PTEN is a tumor suppressor gene
involved in several signaling pathways, most importantly the
PI3K/Akt pathway in which it serves as a phosphatase acting on
PIP3, dephosphorylating PIP3 and producing PIP2-a molecule
that maintains inactivity in the Akt pathway [10,13,14]. PIP3 is a
key regulator of the PI3K/Akt signaling pathway: it recruits Akt to
the membrane surface, an event critical for Akt activation.
Notably, the Akt pathway may be activated via binding of ligands
to cell surface receptors, such as EGFR. Activated Akt regulates
several downstream pathways controlling progression through the
cell cycle, protein synthesis, survival, apoptosis and migration [15–
17]. Loss of PTEN expression, through deletion, mutation or
methylation essentially mimics activation of the Akt pathway as a
result of the accumulation of PIP3 [15], while retention of PTEN
maintains Akt inactivity [17,18]. Although PTEN expression is
ubiquitous across all tissues, only in certain tumor types has it been
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breast, ovaries, prostate, pancreas, skin, and most notably, brain
[19–28].
PTEN-dependent dysregulation of signaling is very frequent in
GBM, with mutation occurring in between 5% and 40% of all
GBM cases, and loss of heterozygosity (LOH) in 60% to 80% of all
cases [8]. Studies conducted in the pre-temozolomide era have
demonstrated that loss of PTEN, either through loss of
heterozygosity (LOH), methylation or mutation, had prognostic
significance [29]. Alternatively, evaluation of cellular PTEN levels
through expression profiling platform as well by immunohisto-
chemistry have been found to be of prognostic significance in
several other studies. This study aims to determine whether loss of
PTEN still holds prognostic significance in newly diagnosed GBM
treated in the temozolomide era.
Materials and Methods
Data Source
A total of 188 patients undergoing craniotomy for resection of a
GBM between 2007 and 2010 were identified. Of these, 33
patients were excluded due to loss to follow-up, incomplete data or
surgery related mortality (30-day post-op mortality). All patients
underwent surgical resection of tumor (biopsy, partial resection,
near gross total resection ($95% resection) and gross total
resection (all enhancing portions of tumor resected). Tumor
grading was based on the WHO classification. This study was
approved by the Institutional Review Board (IRB) of Cedars-Sinai
Medical Center. Due to the retrospective nature of this study, the
IRB approved a waiver of consent and therefore, consent was not
needed (or obtained) for this study.
Prognostic Variables
Patient age, gender, tumor location, post-operative Karnofsky
Performance Scale (KPS), extent of resection, PTEN expression
through IHC and EGFR amplification status as revealed by
Fluorescence in-situ hybridization (FISH), treatment protocol and
overall survival data was collected. For analysis, a patient’s age was
stratified into #65 or greater than 65, extent of resection was
considered high if greater than 95% of the enhancing tumor was
resected (i.e. near gross total resection, gross total resection),
otherwise it was considered low (i.e. biopsy, partial resection). KPS
scales were divided into scores reflecting normal function
(KPS$80) and those demonstrating inability to carry out normal
function (KPS,80). Overall survival in months was calculated
from the date of initial surgery and the social security death index
was used to verify all date of deaths. PTEN expression was defined
as loss or retained while EGFR expression was deemed normal or
abnormal (i.e. amplification or polysomy).
PTEN & EGFR analysis
Evaluation of PTEN staining was performed using immunohis-
tochemistry. Four mm thick paraffin sections were deparaffinized
through xylene, rehydrated by graded alcohol and pretreated with
High pH buffer on Leica Bond-III automated stainer station.
Subsequently, a commercially available antibody to PTEN
(Cascade Biosciences ABM-2052) was used at 1:250 dilution for
32 min incubation at room temperature followed by a detection
with Leica Bond Refine DAB detection system. Nuclei were
counterstained with Hematoxylin (Biocare Medical). A negative
control was performed by omitting the primary antibody and this
revealed no immunoreactivity.
Evaluation of PTEN immunostaining was performed in at least
3 separate fields of the tumor, each containing not less than 50
tumor cells. Endothelial cells within the tumor were used as a
positive control with a rank of staining assigned as 3+. Negative or
weak staining (0+ or 1+) was considered as a loss of expression
(Figure 1). A moderate, uniform cytoplasmic staining of tumor
cells, to a degree lower than of endothelial cells was assigned 2+
intensity and considered to be preserved (Figure 2). Variation
from one field to another was generally low in the most cases of
GBM.
Evaluation of EGFR amplification by FISH was done using
commercially available kit (Vysis, Downers Grove, IL). Dual-
probe analysis was performed with a locus-specific probe for both
EGFR, (the gene is located on chromosome 7), and for
chromosome 7 with chromosome enumeration probe 7 (CEP7).
The tumors with an EGFR/CEP7 signal ratio .2.00 were
classified as having EGFR amplification. Tumors with greater
than 10% nuclei with 3 or more CEP7 signals were classified as
having gain of chromosome 7. Both gain of chromosome 7 and
EGFR amplification frequently occur together in gliomas.
Statistical Analysis
Overall survival was calculated from the time of surgery to
death or time of last follow-up appointment for surviving patients.
Chi-square test was used to evaluate potential differences in
median overall survival by PTEN expression as well as patient
baseline characteristics. Differences in overall survival by PTEN
expression were evaluated via Kaplan-Meier estimates (log-rank
test). Multivariate Cox proportional hazards regression models
were used to explore the predictive role of patient and tumor
characteristics (e.g. KPS, age, PTEN status) in overall survival.
Results
A total of 155 newly diagnosed GBM patients were included in
the study. Median age was 63 years, 64.5% were male and 98.1%
had supratentorial tumors (Table 1). Independent functional level
(KPS$80) was documented in 69.7% of patients, 52.3% had gross
total or near gross total resection and 80.7% were treated with
standard therapy (radiation therapy with concurrent temozolo-
mide), also known as the Stupp protocol [11]. While no significant
associations were found between patient characteristics and PTEN
expression levels, PTEN loss patients were generally older (53.0%
Figure 1. Immunohistochemical analysis, example of a patient
with PTEN loss.
doi:10.1371/journal.pone.0033684.g001
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p=.36), and had lower resection (43.1% vs. 51.9%, p=.28).
Differences in median overall survival (OS) by patient
characteristics were also evaluated. Older ($65), higher function-
ing (KPS$80), high extent of resection, and Stupp treatment were
all statistically significant predictors of longer survival (Table 2). A
total of 72 patients (47%) had retained expression for the PTEN
gene. Independent of PTEN, the median OS was 19.1 months
(95% CI: 15.0–22.5). Differences in median OS survival among
PTEN retained versus loss (20.0 vs. 18.2 months, p=.71) patients
were not statistically significant (Table 2, Figure 3). EGFR
alterations were more common in PTEN loss patients (70.8% vs.
47.8%, p=.01). Patients with EGFR amplification and PTEN loss
had a slightly worse median overall survival compared to patients
with normal EGFR and retained PTEN (20.2 vs. 19.5 months,
p=.55).
Multivariate analysis showed that older age (HR 1.64, CI: 1.02–
2.63, p=.04), low functioning scores (HR 3.57, CI: 2.20–5.79,
p,.0001), and lack of standard treatment (HR 3.98, CI: 2.38–
6.65, p,.0001) were strong predictors of poor survival. PTEN loss
did not significantly increase mortality hazards in the multivariate
model (HR 1.31, CI: 0.85–2.03, p=.22) (Table 3).
Figure 2. Immunohistochemical analysis, example of a patient
with PTEN retained.
doi:10.1371/journal.pone.0033684.g002
Table 1. Patient and tumor characteristics stratified by PTEN expression (retained vs. loss).
Characteristics All patients [N (%)] Retained [N (%)] Loss [N (%)] p value
Total number of patients 155 72 83
Age 0.10
18–49 26 (16.8) 17 (23.6) 9 (10.8)
50–64 53 (34.2) 23 (31.9) 30 (36.1)
$65 76 (49.0) 32 (44.4) 44 (53.0)
Gender 0.60
Female 55 (35.5) 24 (33.3) 31 (37.4)
Male 100 (64.5) 48 (66.7) 52 (62.7)
Tumor Location 0.21
Infratentorial 2 (1.3) 2 (2.8) 0 (0)
Supratentorial 152 (98.1) 70 (97.2) 82 (98.8)
Both 1 (.7) 0 (0) 1 (1.2)
Tumor Size in centimeters 0.20
1–3 19 (17.0) 8 (42.1) 11 (57.9)
3–4 19 (17.0) 12 (63.2) 7 (36.8)
4–6 48 42.9) 17 (35.4) 31 (64.6)
$6 26 (23.2) 13 (50.0) 13 (50.0)
Karnofsky Performance Scale 0.36
80–100 (normal activity) 108 (69.7) 49 (68.1) 59 (71.1)
50–70 (requires assistance) 42 (27.1) 22 (30.6) 20 (24.1)
#40 (disabled) 5 (3.2) 1 (1.4) 4 (4.8)
Extent of Resection* 0.28
Low 73 (47.7) 31 (43.1) 42 (51.9)
High 80 (52.3) 41 (56.4) 39 (48.2)
Standard Treatment** 0.66
Yes 125 (80.7) 57 (79.2) 68 (81.9)
No 30 (19.3) 15 (20.8) 15 (18.1)
*Near-gross/gross-total-resection high resection; biopsy/partial low resection.
**Standard treatment: radiotherapy+temolozolomide.
doi:10.1371/journal.pone.0033684.t001
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Our study found that PTEN loss was not associated with worse
overall survival in newly diagnosed GBM patients of the
temozolomide era. Older age ($65), dependent functional level
(KPS,80), partial resection, and lack of standard therapy were
significant predictors of poor overall survival in newly diagnosed
GBM patients.
PTEN is a tumor suppressor gene that codes for a phosphatase
that acts on PIP3 and regulates the PI3k/Akt pathway [17,30].
Several previous studies, most of which were conducted in the pre-
temozolomide era, demonstrated an adverse prognostic signifi-
cance of PTEN loss of function. For instance, patients with loss of
function mutations of PTEN generally had shorter survival than
patients with PTEN retention [8,29,31–35]. Srividya et al.
reported that 10q23/PTEN homozygous deletion was shown to
be a significant predictor of poor survival (p=.027) in GBM
patients, with average survival in the non-deletion cohort of 24
months, and average survival in the homozygous deletion cohort
of 14 months. Furthermore, stepwise selection model demonstrat-
ed independent prognostic value of homozygous PTEN deletion
(p=.033, HR: 2.013) [8]. Differences in the findings between
Srividya et al. [8] and our study may be explained by the following
factors. Their study included a smaller patient cohort of 73
glioblastoma patients and inclusion was restricted to patients who
underwent either near gross or gross total resection (no patients
had partial resection or biopsy). Furthermore, all patients had
post-operative KPS scores of above 70, as opposed to our study
that included patients with a wide range of KPS scores. Finally, the
only variables included in Srividya et. al [8] study’s multivariate
analysis were patient age and PTEN status. Our study included all
major previously confirmed prognostic factors in a more
representative and much larger group of newly diagnosed GBM
patients treated in the temozolomide era. These factors make our
analysis more representative of all newly diagnosed GBM patients.
Temozolomide is a chemotherapeutic alkylating agent that can
penetrate the blood brain barrier, making it much more effective
in treating brain tumors than previously used chemotherapies
[36]. There is evidence that temozolomide may be more effective
in eradicating GBM cancer cells with PTEN loss and hence, level
Table 2. Median overall survival by patient and tumor characteristics.
Characteristics N %
median overall survival
in months p value
Age 0.0005
18–49 26 16.8 41
50–64 53 34.2 19.5
$65 76 49 15
Gender 0.27
Female 55 35.5 25.5
Male 100 64.5 16
Tumor Location -
Infratentorial 2 1.3 -
Supratentorial 152 98.1 19.1
Both 1 0.7 -
Karnofsky Performance Scale ,.0001
80–100 (normal activity) 108 69.7 25.7
50–70 (requires assistance) 42 27.1 9.8
#40 (disabled) 5 3.2 6.3
Extent of Resection* 0.01
Biopsy 40 26.5 15
partial resection 33 21.9 11.5
near gross total resection 22 14.6 19
gross total resection 56 37.1 22.5
EGFR Expression 0.25
normal 43 38.7 15.8
abnormal 68 61.3 19.5
PTEN Expression 0.71
loss 83 53.6 18.2
Retained 72 46.5 20
Standard Treatment** ,.0001
Yes 125 80.7 22.5
No 30 19.3 5.4
*Near-gross/gross-total-resection high resection; biopsy/partial low resection.
**Standard treatment: radiotherapy+ temolozolomide.
doi:10.1371/journal.pone.0033684.t002
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McEllin et al. [37] reported sensitivity of human glioma cell lines
with PTEN loss to temozolomide. They found that PTEN
deficient glioma cell lines were inefficient at repairing double-
strand breaks induced by Temozolomide, which lead to more
apoptosis. This would explain why PTEN loss does not predict
poor survival in GBM patients treated with temozolomide.
Alternatively, other signaling molecules may circumvent PTEN
retention and activate the PI3k/AKT pathway thus, nullifying the
independent prognostic effects as discussed below.
PTEN, a protein and lipid phosphatase, is an important player
in the PI3k/Akt signaling transduction pathway, a pathway that
regulates critical cell functions such as progression through the cell
cycle, cellular differentiation, migration, and most importantly,
apoptosis (Figure 4) [30,38]. The pathway is initially activated by
the binding of a ligand to a receptor on the plasma membrane,
such as EGFR, HER2 or IGFR, triggering the subsequent
activation of PI3k (also known as phosphatidylinositol 3-kinase) –
whose main function is to phosphorylate the 39 hydroxyl group of
the inoisitol ring of phosphatidylinositol [38]. The product of PI3k,
a molecule called PIP3, acts as the main substrate for PTEN. PIP3
plays an integral role in recruiting Akt to the surface of the
membrane, an event critical for the activation of the PI3k/Akt
pathway. PIP3, a membrane bound protein, triggers PDK1
activation and subsequent Akt phosphorylation and recruitment to
the membrane and it is this Akt activation that directly regulates
all functions of the PI3k pathway. The role of PTEN is to
dephosphorylate PIP3 into PIP2, rendering it incapable of
recruiting Akt to the surface of the membrane and thus activating
the PI3k/Akt pathway (Figure 4). Loss of PTEN results in
accumulation of PIP3. This constitutively activates the PI3k/Akt
pathway inducing tumorigenesis through cell cycle progression,
invasion and loss of apoptosis.
The PI3k/Akt pathway can be up-regulated due to mutation
such as deletion and translocation in one or more of its
downstream effectors [29,39]. While previous literature has
advocated the independent prognostic significance of PTEN loss
in glioblastoma [1,8,29,31], other studies have demonstrated the
importance of EGFR amplification as well as other methods of Akt
pathway activation in tumorigenesis [1,40–42]. In their landmark
paper, Mellinghoff et al. utilized the same immunohistochemistry
analysis of PTEN as the current investigation to demonstrate that
EFFR kinase inhibitors were only effective in patients who had
retained PTEN and an EGFviii mutation [43]. Our study found a
correlation between PTEN loss and EGFR amplification. It has
been reported that synthetic amplification of EGFR in heterozy-
gous PTEN knockout causes mice to develop invasive brain
tumors that closely resemble human glioblastomas [1]. Amplifica-
tion or loss of regulation of several other molecular markers in
addition to EGFR and PTEN involved in the PI3k pathway have
been implicated in human glioblastoma: platelet-derived growth
factor receptor (PDGFR), fibroblast growth factor receptor
(FGFR), and other tyrosine kinase receptors [1,12,21]. Other
studies have demonstrated the significance of yet other effectors in
Table 3. Multivariate analysis of Overall Survival: Adjusted
hazards ratio (HR) of mortality, 95% Confidence Intervals (CI),
and p values.
Characteristics HR 95% CI p value
Age in years (ref: #65)
age.65 1.64 1.02–2.63 0.04
Karnofsky Performance Score
(ref: KPS$80)
KPS,80 3.57 2.20–5.79 ,.0001
Low vs. high extent of
resection
1.39 0.89–2.17 0.14
Lack of Standard Treatment 3.98 2.38–6.65 ,.0001
PTEN loss 1.31 0.85–2.03 0.22
doi:10.1371/journal.pone.0033684.t003
Figure 3. Kaplan-Meir overall 260 survival functions for newly diagnosed glioblastoma patients according to PTEN expression
(dashed: PTEN loss, solid: PTEN retained).
doi:10.1371/journal.pone.0033684.g003
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pathway [1,7,15,44–47].
While PTEN expression versus retention does not indepen-
dently demonstrate prognostic significance, other molecules
involved in the PI3k/Akt pathway could hold independent or
correlative prognostic significance. For example, although Pelloski
et al. [48] found no significant association between activated Akt
and overall survival, their univariate results did show decreased
survival associated with other members of the Akt pathway
(p70S6K, mTOR). However, that effect was not significant in their
final multivariate model. Pelloski et al. also attempted to associate
the loss of PTEN to Akt expression in 142 patients with
glioblastoma and found that there was no inverse correlation
between PTEN and Akt as assessed by immunohistochemistry.
Other large studies in breast cancer and melanoma have also
failed to detect the inverse relationship between PTEN and Akt
and some have even reported an unexpected positive correlation
[36,49]. This can be accounted for by the fact that several other
proteins in addition to PTEN are involved in Akt activation and its
recruitment to the membrane—such as PDK1, insulin and insulin-
Figure 4. Role of PTEN in the PI3K-AKT signaling pathway.
doi:10.1371/journal.pone.0033684.g004
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and thus activating Akt [15,44,45,50]. For example, if PDK1
constitutively activates Akt, thus activating the PI3k pathway, Akt
activation occurs independently of PTEN loss or retention,
resulting in PTEN-independent constitutive activation of the
PI3k/Akt pathway. Furthermore, there are other direct methods
of Akt activation not involving PTEN: modifications to Akt itself –
such as regions of the protein involved in membrane recruitment
and also resulting in constitutive Akt activation independent of
PTEN status [44,45,50]. The fact that an inverse correlation
between PTEN and Akt was not found, in a large number of GBM
samples, supports the idea of a complex relationship between
PTEN, Akt and their regulators and effectors.
Our study evaluating the role of PTEN as a prognostic marker
in the temozolomide era included the largest, most representative
group of newly diagnosed GBM patients. After controlling for all
key prognostic factors we found that PTEN status alone did not
hold independent prognostic significance and did not predict
overall survival. These findings imply a complex molecular
relationship between PTEN and its regulators and effectors in
the tumorigenesis of glioblastoma. Additionally, there is evidence
that temozolomide may be preferentially effective in eradicating
GBM cancer cells with PTEN loss and hence, level the outcomes
between the PTEN retained and PTEN loss groups.
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